April 17, 2020 — In an effort to suppress and ultimately stifle the spread of the global COVID-19 pandemic, the world’s scientific and medical communities are turning to treatments containing omega-3 fatty acids and fish oil for help.
Clinical trials will soon be run by KD Pharma Group and its partner, SLA Pharma, to test the effectiveness of its new drug, EPAspire, on patients symptomatic with inflammatory cytokines, which is believed to play a part in COVID-19’s progression. The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has moved to expedite trials of the drug, while discussions with authorities in other European countries are underway, KD Pharma announced on 14 April.